A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain

Table 5 Summary of medians, range and statistical comparisons for the Client Specific Outcome Measures scores (CSOM) at D0, D14 and D28 of the study

Group	D0	D14	D28	D0 minus D14	Within group change P-value	D0 minus D28	Within group change P-value
NV-01	6.0 (4 – 11)	4.0 (0 – 7)	3.5 (0 – 9)	3.0 (-1 – 8)	0.004	3.0 (0 – 6)	0.001
Placebo	6.0 (5 – 11)	5.0 (3 – 8)	6.0 (3 – 9)	0.0 (-1 – 3)	0.031	0.0 (-1 – 3)	0.078
Between group comparison P-value	0.548	0.011	0.032	0.038		0.009

Decreases in scores signify improvement, and positive values for change indicate improvement. Significant P-values are denoted in bold type.

ISSN: 1746-6148